Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.

IF 4.9 2区 医学 Q1 CLINICAL NEUROLOGY
Thomas D Meyer, Maya Ibrahim, Lauren Vale, Jair C Soares
{"title":"Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.","authors":"Thomas D Meyer, Maya Ibrahim, Lauren Vale, Jair C Soares","doi":"10.1016/j.jad.2024.12.044","DOIUrl":null,"url":null,"abstract":"<p><p>Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic use in individuals with BD. Using the Time-Line Follow Back (TLFB) method, we assessed mood symptoms, substance use, and other mental health-related variables in the month before and three months following participants' most recent psychedelic experience. Results showed a significant reduction in depressive symptoms and cannabis use, an increase in the number of days without mental health symptoms, and an increase in the number of days with hallucinogen use. Importantly, no significant changes in (hypo)manic, psychotic, or anxiety symptoms were observed. These findings suggest that psychedelics may hold potential as a safe and effective treatment for BD, though further research, including randomized controlled trials, is needed.</p>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jad.2024.12.044","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic use in individuals with BD. Using the Time-Line Follow Back (TLFB) method, we assessed mood symptoms, substance use, and other mental health-related variables in the month before and three months following participants' most recent psychedelic experience. Results showed a significant reduction in depressive symptoms and cannabis use, an increase in the number of days without mental health symptoms, and an increase in the number of days with hallucinogen use. Importantly, no significant changes in (hypo)manic, psychotic, or anxiety symptoms were observed. These findings suggest that psychedelics may hold potential as a safe and effective treatment for BD, though further research, including randomized controlled trials, is needed.

使用迷幻剂与躁郁症--对娱乐性使用及其对心理健康影响的调查。
最近,迷幻剂(如迷幻素)因其在治疗抑郁症和其他精神健康问题方面的潜在疗效而备受关注。然而,由于担心躁狂症或精神病,大多数临床试验都将双相情感障碍(BD)患者排除在外。本研究旨在系统研究娱乐性使用迷幻药对双相情感障碍患者的影响。我们采用时间线回溯(TLFB)方法,评估了参与者最近一次迷幻药体验前一个月和体验后三个月的情绪症状、药物使用和其他心理健康相关变量。结果显示,抑郁症状和大麻使用量明显减少,无精神健康症状的天数增加,使用致幻剂的天数增加。重要的是,在(低)躁狂症、精神病或焦虑症状方面没有观察到明显的变化。这些研究结果表明,迷幻剂有可能作为一种安全有效的治疗方法来治疗BD,但还需要进一步的研究,包括随机对照试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of affective disorders
Journal of affective disorders 医学-精神病学
CiteScore
10.90
自引率
6.10%
发文量
1319
审稿时长
9.3 weeks
期刊介绍: The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信